Candidate Galeno 2024
Efanesoctocoq alfa (Altuvoct®) from Swedish company Orphan Biovitrum AB is the first representative of the High-SustainedFactor-VIII (HSF) class of factor VIII drugs. The recombinant fusion protein can reduce the risk of bleeding and improve quality of life in patients with severe hemophilia A.